Pragmatic trials

New England Journal of Medicine

Volumn 375, Issue 5, 2016, Pages 454-463

  Ford, Ian ^a   Norrie, John ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL STUDY; DATA ANALYSIS; EXPERIMENTAL DESIGN; FOLLOW UP; HEALTH SERVICE; HUMAN; MEDICAL RESEARCH; MEDICAL SERVICE; MEDICAL SOCIETY; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRAGMATIC TRIAL; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; PATIENT SELECTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS; TREATMENT OUTCOME;

FOLLOW-UP STUDIES; HUMANS; PATIENT SELECTION; PRAGMATIC CLINICAL TRIALS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84982175156     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1510059     Document Type: Review

References (48)

1. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967; 20: 637-48.
2. Developing and evaluating complex interventions: new guidance. London: Medical Research Council, 2008 (www .mrc .ac .uk/documents/pdf/complex-interventions-guidance).
3. Thorpe KE, Zwarenstein M, Oxman AD, et al. A Pragmatic-Explanatory Continuum Indicator Summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009;62:464-75.
4. Roland M, Torgerson DJ. What are pragmatic trials? BMJ 1998; 316: 285.
5. Godwin M, Ruhland L, Casson I, et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Meth-odol 2003;3:28.
6. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 2005;365:82-93.
7. Devereaux PJ, Bhandari M, Clarke M, et al. Need for expertise based randomised controlled trials. BMJ 2005; 330: 88.
8. Ernst E, Canter PH. Limitations of "pragmatic" trials. Postgrad Med J 2005; 81:203.
9. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009;10:37.
10. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med 2009; 151: 206-9.
11. Kent DM, Kitsios G. Against pragmatism: on efficacy, effectiveness and the real world. Trials 2009; 10: 48.
12. Eldridge S. Pragmatic trials in primary health care: what, when and how? Fam Pract 2010;27:591-2.
13. Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci 2011;13:217-24.
14. Ware JH, Hamel MB. Pragmatic trials - guides to better patient care? N Engl J Med 2011;364:1685-7.
15. Mitka M. FDA advisory decision highlights some problems inherent in pragmatic trials. JAMA 2011; 306: 1851-2.
16. Chalkidou K, Tunis S, Whicher D, Fowler R, Zwarenstein M. The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research. Clin Trials 2012; 9: 436-46.
17. Ratner J, Mullins D, Buesching DP, Cantrell RA. Pragmatic clinical trials: U.S. payers' views on their value. Am J Manag Care 2013;19(5):e158-65.
18. Kim SYH, Miller FG. Informed consent for pragmatic trials - the integrated consent model. N Engl J Med 2014; 370: 769-72.
19. Sugarman J, Califf RM. Ethics and regulatory complexities for pragmatic clinical trials. JAMA 2014; 311: 2381-2.
20. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984; 3: 409-22.
21. Anderson ML, Griffin J, Goldkind SF, et al. The Food and Drug Administration and pragmatic clinical trials of marketed medical products. Clin Trials 2015; 12: 511-9.
22. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 2015; 350: h2147.
23. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008;337:a2390.
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 20 02;360:7-22.
25. Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004; 364: 1321-8.
26. Fröbert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2013; 369: 1587-97.
27. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011;365:2088-97.
28. Pickard R, Lam T, MacLennan G, et al. Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisa-tion in hospital: a multicentre randomised controlled trial. Lancet 2012; 380: 1927-35.
29. Califf RM, Sugarman J. Exploring the ethical and regulatory issues in pragmatic clinical trials. Clin Trials 2015; 12: 436-41.
30. Campbell R, Starkey F, Holliday J, et al. An informal school-based peer-led intervention for smoking prevention in adolescence (ASSIST): a cluster randomised trial. Lancet 2008;371:1595-602.
31. ClinicalTrials.gov. High-sensitivity tro-ponin in the evaluation of patients with acute coronary syndrome (High-STEACS) trial (https://clinicaltrials.gov/ct2/show/ NCT01852123).
32. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials 2007; 28:182-91.
33. Treweek S, Lockhart P, Pitkethly M, et al. Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. BMJ Open 2013; 3.
34. Relton C, Torgerson D, O'Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design. BMJ 2010; 340: c1066.
35. McFadden E, Bashir S, Canham S, et al. The impact of registration of clinical trials units: the UK experience. Clin Trials 2015;12:166-73.
36. Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded End-point (PROBE) study: a novel design for intervention trials. Blood Press 1992; 1: 113-9.
37. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodip-ine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
38. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103-16.
39. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996;275:1897-902.
40. The West of Scotland Coronary Prevention Study Group. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiologi-cal study. J Clin Epidemiol 1995; 48: 1441-52.
41. Barry SJ, Dinnett E, Kean S, Gaw A, Ford I. Are routinely collected NHS administrative records suitable for endpoint identification in clinical trials? Evidence from the West of Scotland Coronary Prevention Study. PLoS ONE 2013; 8(9): e75379.
42. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-86.
43. McConnachie A, Walker A, Robertson M, et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Eur Heart J 2014; 35:290-8.
44. PROMIS (http://www.healthmeasures.net/explore-measurement-systems/promis).
45. Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011;364:1695-707.
46. Institute of Medicine. The learning healthcare system: workshop summary. Washington, DC: National Academies Press, 2007.
47. Vickers AJ. Clinical trials in crisis: four simple methodologic fixes. Clin Trials 2014;11: 615-21.
48. Califf RM. Commentary on Vickers. Clin Trials 2014;11:626-7.